Clinical trials: Placebo Response
Major Depressive Disorder
The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD who have had an inadequate response to…
- Trial name
- NCT03739203
- Testing
- Cariprazine, Antidepressant Therapy (ADT)
- Where
- 112 sites in United States, Canada and 6 more
- Volunteers
- 752 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)
This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF-alpha therapy.
- Trial name
- SCRIPT (NCT00476996)
- Testing
- Leflunomide, Methotrexate, Ocrelizumab
- Where
- 266 sites in United States, Argentina and 23 more
- Volunteers
- 836 people
- Sponsor
- Genentech, Inc.
Healthy Volunteers
A Study to Investigate the Impact of Dose and Dosing Frequency of AZD8848 on the Response on Biomarkers
The study will investigate how the dose of AZD8848 and the dosing frequency will affect the immunological/inflammatory response by measuring the production of biomarkers in blood and nasal lavage.
- Trial name
- NCT01203124
- Testing
- AZD8848
- Where
- Sweden
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Subjects
Dose Response and Efficacy of GW842166 in Pain
The purpose of this study is to assess the dose response and efficacy of single and repeat doses of GW842166 in healthy volunteers using pharmacodynamic pain assessments.
- Trial name
- NCT00554762
- Testing
- GW842166X
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
The purpose of this study is to determine whether Apremilast is safe and effective in the treatment of patients with rheumatoid arthritis, specifically in improving signs and symptoms of rheumatoid arthritis (tender and swollen…
- Trial name
- NCT01285310
- Testing
- Apremilast 30 mg, Apremilast 20 mg
- Where
- 50 sites in United States, Czechia and 2 more
- Volunteers
- 237 people
- Sponsor
- Amgen
Rheumatoid Arthritis
BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis
This Phase 2b study is designed to evaluate the efficacy and safety of BG9924 given subcutaneously (SC) versus placebo in participants with active rheumatoid arthritis (RA) who have previously had an inadequate response to…
- Trial name
- NCT00458861
- Testing
- BG9924
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Biogen
Idiopathic Parkinson's Disease
Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
This randomized, multicenter, placebo-controlled, double-blind study will evaluate the efficacy and safety of inhaled CVT 301 compared with placebo in PD patients experiencing motor response fluctuations (OFF phenomena) as an…
- Trial name
- SPAN-PD™ (NCT02240030)
- Testing
- CVT-301 Low Dose, CVT-301 High Dose
- Where
- 74 sites in United States, Canada and 3 more
- Volunteers
- 351 people
- Sponsor
- Acorda Therapeutics
Type 2 Diabetes Mellitus
Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM
This study is a randomized, double-blind (Investigator and study subject), placebo controlled multiple dose sequential ascending dose study that will enroll up to 47 male and female subjects with type 2 diabetes mellitus (T2DM)…
- Trial name
- NCT02581657
- Testing
- PE0139 Injection
- Where
- 6 sites in United States
- Volunteers
- 37 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Arthritis, Psoriatic
A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy
The purpose of this study is to evaluate guselkumab efficacy versus placebo in participants with active psoriatic arthritis (PsA) and an inadequate response to Anti-Tumor Necrosis Factor Alpha (TNF-alpha) therapy by assessing the…
- Trial name
- COSMOS (NCT03796858)
- Testing
- Guselkumab 100 mg
- Where
- 117 sites in Belgium, Bulgaria and 12 more
- Volunteers
- 285 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Rheumatoid Arthritis
A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment
This 2 arm study will compare 2 treatment strategies based on tocilizumab in combination with methotrexate or placebo in patients with moderate to severe rheumatoid arthritis.
- Trial name
- NCT00810199
- Testing
- tocilizumab [RoActemra/Actemra], methotrexate
- Where
- 137 sites in United States, Brazil and 18 more
- Volunteers
- 556 people
- Sponsor
- Hoffmann-La Roche
Gout
Combining Lesinurad With Allopurinol in Inadequate Responders
This study that compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with allopurinol to allopurinol alone in subjects with gout who have had an inadequate response to…
- Trial name
- CLEAR 1 (NCT01510158)
- Testing
- Lesinurad, Allopurinol
- Where
- 165 sites in United States
- Volunteers
- 607 people
- Sponsor
- Ardea Biosciences, Inc.
Rheumatoid Arthritis
A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone
The primary objectives of this study are to compare the efficacy, safety, and tolerability of upadacitinib 30 mg once daily (QD) and 15 mg QD versus placebo for the treatment of signs and symptoms of adults with moderately to…
- Trial name
- SELECT-NEXT (NCT02675426)
- Testing
- Upadacitinib
- Where
- 167 sites in United States, Argentina and 36 more
- Volunteers
- 661 people
- Sponsor
- AbbVie
Acute Respiratory Distress Syndrome, Respiratory Failure
MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients
This is a phase IIa, dose-ranging, proof-of-concept study of MRG-001 in patients with ARDS. The aim is to determine the safety and preliminary efficacy of MRG-001 across two dose ranges.
- Conditions
- Acute Respiratory Distress Syndrome, Respiratory Failure, Respiratory Distress Syndrome, Respiratory Tract Diseases
- Trial name
- SUMMIT (NCT06308926)
- Testing
- MRG-001 (Low-dose), MRG-001 (High-dose)
- Volunteers
- 60 people
- Sponsor
- MedRegen LLC
Atrial Flutter, Atrial Fibrillation
Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter
The purpose of this study is to demonstrate the effectiveness of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm.
- Trial name
- NCT00115791
- Testing
- RSD1235
- Where
- 54 sites in United States, Argentina and 5 more
- Volunteers
- 276 people
- Sponsor
- Astellas Pharma Inc
Neuroinflammatory Response
Safety & PK of Single Doses of MT1980
MT1980 is being developed as a treatment for neuroinflammation (an inflammatory response in the brain and/or spinal cord). Much research has focused on the central role of neuroinflammation in the pathogenesis of many conditions…
- Trial name
- NCT05429840
- Testing
- MT1980
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Monument Therapeutics Limited
Hidradenitis Suppurativa (HS)
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
The purpose of this study is to determine whether IFX-1 is safe and effective in the treatment of moderate to severe hidradenitis suppurativa.
- Trial name
- SHINE (NCT03487276)
- Testing
- IFX-1
- Where
- 41 sites in United States, Bulgaria and 7 more
- Volunteers
- 179 people
- Sponsor
- InflaRx GmbH
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)
The goal of this clinical trial is to learn whether the bacterial vaccine MV130 helps reduce the number of exacerbations in adults with moderate to severe COPD. It will also assess the safety and immune effects of MV130.
- Trial name
- MV130 (NCT01842360)
- Testing
- MV130
- Where
- 7 sites in Spain
- Volunteers
- 198 people
- Sponsor
- Inmunotek S.L.
Anthocyanins
Intestinal Inflammatory and Metabolic Responses to a High Fat Meal and Plant Polyphenol Blend
This study will investigate the beneficial effects of supplementation with a plant polyphenol blend rich in anthocyanins on parameters of inflammation and metabolic responses following a challenge with a high-fat (HF) meal.
- Trial name
- NCT03309982
- Testing
- Plant polyphenol blend
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pharmanex
Gastrointestinal Digestion, Healthy
Clinical Trial on Digestive Enzymes: Effects on Post-Meal Response to High-Macronutrient Meals
This study aims to show how digestive enzyme supplements help the body break down fats, proteins, and carbohydrates, especially after eating a high-macronutrient meal.
- Conditions
- Gastrointestinal Digestion, Healthy, Gastrointestinal Wellbeing, Gastrointestinal Supplements
- Trial name
- NCT06949735
- Testing
- Digestive Enzyme Blend
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pancap Pharma Inc.
Rheumatoid Arthritis
A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo
A Randomized, Double Blind, Placebo Controlled Phase 2 Study To assess the Immune Response Following Administration of Influenza and Pneumococcal Vaccines to Subjects with Rheumatoid Arthritis receiving CP-690,550 with and…
- Trial name
- NCT01359150
- Testing
- CP-690,550
- Where
- 57 sites in United States, Poland
- Volunteers
- 223 people
- Sponsor
- Pfizer